longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

BioMarin Pharma

BMRN

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 174.23, within the reasonable range, cheaper than 26.84% of the time in the past 5 years, and the industry ranks 65/601, the industry Median -2.50.

174.23xP/E
$65.68Stock price
$0.38Earnings per share
174.23xP/E
Stock price$65.68Earnings per share$0.38

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
77.82x
Typical range
21.88x–233.54x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
04488132176

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
BMRNUSBioMarin Pharma
174.23x62.07%$12.71B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.